Drugmaker AstraZeneca has agreed to buy Belgium-based biotechnology firm EsoBiotec for up to $1 billion, it said on Monday, ...
Feb 20 (Reuters) - AstraZeneca (AZN.L), opens new tab will buy longtime partner FibroGen's (FGEN.O), opens new tab China unit for about $160 million to gain rights to its anemia drug in the ...
7d
MedPage Today on MSNCan Flu Shot Nudges Lead to Fewer COVID Vaccinations?Receiving an electronic reminder about influenza vaccination appeared to decrease COVID vaccination rates. Further study of ...
4d
MedPage Today on MSNNCI Flags 'Cancer Moonshot'; Dr. Hologram Will See You; Fraud Crackdown ContinuesThe American Cancer Society awarded its 2025 Medal of Honor to W. Kimryn Rathmell, MD, PhD, renowned kidney cancer expert and ...
The once-daily pill combines Opko’s long-acting GLP-1/glucagon dual agonist peptide, dubbed OPK-88006, with Entera’s N-Tab ...
AstraZeneca is paying $160 million for FibroGen’s China business, giving the U.K.-based Big Pharma the regional rights to oral anemia drug roxadustat. The two companies' relationship around ...
AstraZeneca has advanced its push to make camizestrant a blockbuster, reporting a phase 3 win for the oral SERD at an interim analysis. The trial hit on progression-free survival (PFS), its ...
AstraZeneca PLC (LON:AZN) announced a healthy earnings result recently, and the market rewarded it with a strong uplift in the stock price. This reaction by the market reaction is understandable ...
AstraZeneca is a company with a turbulent history but, for now, a promising future. We take a look at the company's story, from its creation as a merger of two equals, to its recent major ...
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. AstraZeneca has been hit with a US class action lawsuit that claims the UK’s largest listed company ...
Find out more about how we test, analyze, and rate. The Samsung Galaxy Tab S10 Plus has arrived with little fanfare, which seems unfair given that it is the Android tablet world's best answer to ...
AstraZeneca said its breast cancer drug candidate showed positive results in a late stage trial, with improved progression-free survival in patients. The British pharma giant said Wednesday that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results